146 related articles for article (PubMed ID: 17051621)
1. Designer T cells by T cell receptor replacement.
Sommermeyer D; Neudorfer J; Weinhold M; Leisegang M; Engels B; Noessner E; Heemskerk MH; Charo J; Schendel DJ; Blankenstein T; Bernhard H; Uckert W
Eur J Immunol; 2006 Nov; 36(11):3052-9. PubMed ID: 17051621
[TBL] [Abstract][Full Text] [Related]
2. Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors.
Gladow M; Uckert W; Blankenstein T
Eur J Immunol; 2004 Jul; 34(7):1882-91. PubMed ID: 15214036
[TBL] [Abstract][Full Text] [Related]
3. Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes.
Pouw NM; Westerlaken EJ; Willemsen RA; Debets R
J Gene Med; 2007 Jul; 9(7):561-70. PubMed ID: 17471588
[TBL] [Abstract][Full Text] [Related]
4. Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.
Reuss S; Biese P; Cosset FL; Takeuchi Y; Uckert W
Gene Ther; 2007 Apr; 14(7):595-603. PubMed ID: 17235289
[TBL] [Abstract][Full Text] [Related]
5. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells.
Sommermeyer D; Uckert W
J Immunol; 2010 Jun; 184(11):6223-31. PubMed ID: 20483785
[TBL] [Abstract][Full Text] [Related]
6. Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy.
Engels B; Uckert W
Mol Aspects Med; 2007 Feb; 28(1):115-42. PubMed ID: 17307249
[TBL] [Abstract][Full Text] [Related]
7. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer.
Mommaas B; van Halteren AG; Pool J; van der Veken L; Wieles B; Heemskerk MH; Goulmy E
Haematologica; 2005 Oct; 90(10):1415-21. PubMed ID: 16219579
[TBL] [Abstract][Full Text] [Related]
8. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
[TBL] [Abstract][Full Text] [Related]
9. Transfection of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate cross-reactivity to related compounds.
Schmid DA; Depta JP; Lüthi M; Pichler WJ
Mol Pharmacol; 2006 Jul; 70(1):356-65. PubMed ID: 16617162
[TBL] [Abstract][Full Text] [Related]
10. Rapid re-expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen-specific stimulation.
van Loenen MM; Hagedoorn RS; de Boer R; van Egmond EH; Falkenburg JH; Heemskerk MH
J Immunother; 2011 Mar; 34(2):165-74. PubMed ID: 21304404
[TBL] [Abstract][Full Text] [Related]
11. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
[TBL] [Abstract][Full Text] [Related]
12. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer.
Kieback E; Charo J; Sommermeyer D; Blankenstein T; Uckert W
Proc Natl Acad Sci U S A; 2008 Jan; 105(2):623-8. PubMed ID: 18182487
[TBL] [Abstract][Full Text] [Related]
13. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells.
Lyons GE; Roszkowski JJ; Man S; Yee C; Kast WM; Nishimura MI
Cancer Immunol Immunother; 2006 Sep; 55(9):1142-50. PubMed ID: 16374636
[TBL] [Abstract][Full Text] [Related]
14. T-cell engineering for cancer immunotherapy.
Sadelain M
Cancer J; 2009; 15(6):451-5. PubMed ID: 20010162
[TBL] [Abstract][Full Text] [Related]
15. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
16. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells.
Scholten KB; Kramer D; Kueter EW; Graf M; Schoedl T; Meijer CJ; Schreurs MW; Hooijberg E
Clin Immunol; 2006 May; 119(2):135-45. PubMed ID: 16458072
[TBL] [Abstract][Full Text] [Related]
17. On the pathogenicity of autoantigen-specific T-cell receptors.
Burton AR; Vincent E; Arnold PY; Lennon GP; Smeltzer M; Li CS; Haskins K; Hutton J; Tisch RM; Sercarz EE; Santamaria P; Workman CJ; Vignali DA
Diabetes; 2008 May; 57(5):1321-30. PubMed ID: 18299317
[TBL] [Abstract][Full Text] [Related]
18. Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity.
Depta JP; Altznauer F; Gamerdinger K; Burkhart C; Weltzien HU; Pichler WJ
J Allergy Clin Immunol; 2004 Mar; 113(3):519-27. PubMed ID: 15007356
[TBL] [Abstract][Full Text] [Related]
19. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.
Okamoto S; Mineno J; Ikeda H; Fujiwara H; Yasukawa M; Shiku H; Kato I
Cancer Res; 2009 Dec; 69(23):9003-11. PubMed ID: 19903853
[TBL] [Abstract][Full Text] [Related]
20. T cell receptor gene therapy for autoimmune diseases.
Fujio K; Okamura T; Okamoto A; Yamamoto K
Ann N Y Acad Sci; 2007 Sep; 1110():222-32. PubMed ID: 17911437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
